Format

Send to

Choose Destination
Vaccine. 2014 Jul 31;32(35):4515-21. doi: 10.1016/j.vaccine.2014.06.010. Epub 2014 Jun 17.

Factors associated with humoral immune response to pandemic A/H1N1(v) 2009 influenza vaccine in cystic fibrosis.

Author information

1
Inserm, CIC 1417, Paris, France; Université Paris Descartes, Paris Sorbonne Cité, Paris, France; Assistance-Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin-Pasteur, Paris, France.
2
INSERM, U707, Paris, France.
3
Assistance-Publique Hôpitaux de Paris, Hôpital Cochin, Service de Virologie, Paris, France.
4
Hôpital Foch, Service de Pneumologie, Suresnes, France.
5
Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Chirurgie Thoracique, Paris, France.
6
Centre Hospitalier Intercommunal de Créteil, Centre de Ressources et de Compétences en Mucoviscidose, Créteil, France.
7
Assistance-Publique Hôpitaux de Paris, Hôpital Trousseau, Centre de Ressources et de Compétences en Mucoviscidose, Paris, France.
8
Assistance-Publique Hôpitaux de Paris, Hôpital Necker, Service de Pneumologie- Allergologie Pediatrique et Centre de Ressources et de Compétences en Mucoviscidose, Paris, France.
9
Assistance-Publique Hôpitaux de Paris, Hôpital Cochin, Service de Pneumologie, Centre de Ressources et de Compétences en Mucoviscidose, Paris, France.
10
Université Paris Descartes, Paris Sorbonne Cité, Paris, France; Assistance-Publique Hôpitaux de Paris, Hôpital Necker, Service de Pneumologie- Allergologie Pediatrique et Centre de Ressources et de Compétences en Mucoviscidose, Paris, France; INSERM U 1151, Paris, France. Electronic address: isabelle.sermet@nck.aphp.fr.

Abstract

Influenza vaccination is recommended in cystic fibrosis patients. The objective of this study was to assess the immunogenicity of vaccination against 2009 pandemic A/H1N1 influenza and to study the factors associated with the immune response in patients with cystic fibrosis. 122 patients with cystic fibrosis were enrolled in a prospective study and received 1 dose of 2009/H1N1v adjuvanted vaccine, or for children <2 years and lung-transplanted patients, two doses of non-adjuvanted 2009/H1N1v vaccine administered 21 days apart. Hemagglutination inhibition antibodies were assessed before and 21 days after vaccination and at least 6 months after vaccination. After vaccination, 85% of the patients had an influenza antibody titer ≥1:40 and 69% seroconverted. 13% of the transplanted patients seroconverted compared with 72% of the non-transplanted patients. In this latter group, non-adjuvanted vaccine and low body mass index were independently associated with lower response to vaccination. 86% of the non-transplanted patients with normal BMI and receiving adjuvanted vaccine seroconverted. Persistence of seroprotection 10 months after vaccination was found in 50% of the patients. In patients with cystic fibrosis, malnutrition and receipt of non-adjuvanted vaccine were associated with lower immune response to pandemic influenza vaccination. Our data also suggest a potential defect in the immune response to influenza vaccination of patients with cystic fibrosis and raise the question of whether a different immunization strategy is needed.

KEYWORDS:

Adjuvanted vaccine; Cystic fibrosis; Influenza; Malnutrition; Pandemic; Vaccine

PMID:
24950362
DOI:
10.1016/j.vaccine.2014.06.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center